Claims

1. Conjugate comprising at least one compound carrying carboxyl groups and an oligomer which consists of peptidically linked lysin monomer units, ~~and which is either built up from more than 50% (based on the number of monomer units) of lysine monomer units or comprises at least 10 successive monomer units which are built up from at least 70% (based on the number of monomer units) of lysine monomer units,~~ wherein within the oligomer said lysine monomer units are bonded via the ε-amino group of their side chain, wherein the proportion of carboxyl groups in the molecular weight of the compound carrying carboxyl groups is greater than 30% in the case of the compound carrying carboxyl groups, that at least one compound carrying carboxyl groups which is conjugated to the oligomer contains two or more free carboxyl groups, ~~and~~ that the conjugate contains between 3 and 6 compounds carrying carboxyl groups per 10 monomer ~~units characterised in that the oligomer consists only of ε-lysine monomer units~~ and that the oligomer has a chain length of 10 to 50 monomer units.

2. Conjugate according to Claim 1, characterised in that in addition at least one active compound is covalently bonded to the conjugate.

3. Conjugate according to Claim 2, characterised in that the active compound is selected from the group of the immunosuppressants, for example azathioprine, mycophenolate-mofetil, ciclosporin, tacrolimlls, sirolimus, fingolimod or triptolide, cytostatics, for example bleomycin, dactinomycin, mitomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantron, amsacrine, doxofluridine, cisplatin, carboplatin, oxaliplatin, satraplatin, camptothecin, toptecan, irinotecan, etoposide, teniposide, cyclophosphamide, trofosfamide, melphalan, chlommbucil, estramustine, busulfan, chlorambucil, chlormethine, treosulfan, carmustine, lomustine, nimustine, procarbazine, streptozocine, dacarbazine, ifosfamide, temozolomide, thiotepa, vinorelbine, vincristine, vinblasirie, vindesine, paclitaxel, docetaxel, methotrexate, pemetrexed, raltitrexed, fluorouracil, capecitabine, cytosinarabinoside, gemcitabine, tioguanine, pentostatin, mercaptopurine, fludarabine, caldribine, hydroxyl-carbamide, mitotane, azacitidine, cytarabine, nelarabine, bortezomib, anagrelide, in particular the protein kinase inhibitors, such as, for example, imatinib, ,erlotinib, sunitinib, sorafenib, dasatinib, lapatinib or nilotinib, immunotherapeutic agents, for example cetuximab, alemtuz-

umab and bevacizumab, antiphlogistics, for example naproxen, ibuprofen, indometacin, prednisolone, prednisone, hydrocortisone or budesonide, antibiotics, in particular the penicillins, such as, for example, benzylpenicillin, methicillin or amoxicillin, the cephalosporins, such as, for example, cefuroxim, cefotaxim, cefadroxil or cefixim, the β-lactamase inhibitors, such as, for example, clavulanic acid, sulbactam ortazobactam, the carbapenems, such as, for example, imipenem or meropenem, the monobactams, such as, for example, aztreonam, the tetracyclines, such as, for example, tetracycline, chlortetracycline, oxytetracycline, doxycycline minocycline or tigecycline, the macrolide antibiotics, such as, for example, erythromycin A, the glycopeptide antibiotics, such as, for example, vancomycin, the enediynes, such as, for example, calicheamicin, virostatics, for example aciclovir, alaciclovir, ganciclovir, valganciclovir, pencielovir, famdelovir, brivudine, cidofovir, foscarnet, idoxuridine or tromantadine, antihypertensives, in particular the ACE inhibitors, such as, for example, benazepril, captopril, cilazapril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril or zofenopril, the sartans, such as, for example, losartan, balsartan, irbesartan, candesartan, eprosartan, olmesartan or telmisartan, the renin inhibitors, such as, for example, aliskiren, and the beta blockers, such as; for example, proproanolol, pindolol, sotalol, bopindolol, atenolol, bisorpolol, celiprolol, esmolol, metoprolol, nebivolol, oxprenolol, carvedilol or labetalol, uricosurics, for example probenecid or benzbromarone, or diuretics, for example acetazolamide, furosemide, torasemide, bum-etanide, piretanide, azosemide, etacrynic acid, etozoline, hydrochloro-thiazide, benzthiazide, ctllorothiazide, chlorthalidone, indapamide, rnefruside, metolazone, clopamide, xipamide, hydroflumethiazide, methyclothiazide, polythiazide, amiloride, tria-meterene, spironolactone, canrenone, eplerenone or spironolactone.

~~4. Conjugate according to one or more of Claims 1 to 3, characterised in that the oligomer has a chain length of 10 to 50 monomer units.~~

~~5~~4. Conjugate according to one or more of Claims 1 to 3~~4~~, characterised in that the oligomer consists of ε-polylysine.

5~~6~~. Conjugate according to one or more of Claims 1 to 4~~5~~, characterised in that at least one compound carrying carboxyl groups is bonded, directly or via a spacer, to the amino group of an ε-lysine monomer unit.

67. Conjugate according to one or more of Claims 1 to 56, characterised in that at least one compound carrying carboxyl groups is a complexing agent.

78. Process for the preparation of a conjugate corresponding to one or more of Claims 1 to 67 which comprises at least the following process steps:

a) provision of an oligomer which consists of consists of peptidically linked lysine monomer units

~~and which is either built up from more than 50% (based on the number of monomer units) of lysine monomer units or comprises at least 10 successive monomer units which are built up from at least 70% (based on the number of monomer units) of lysine monomer units~~, wherein within the oligomer said lysine monomer units are bonded via the ε-amino group of their side chain and the oligomer has a chain length of 10 to 50 monomer units; and

b) conjugation of at least one optionally activated compound carrying carboxyl groups to the oligomer from step a) ~~that at least one compound carrying carboxyl groups which is conjugated to the oligomer contains two or more free carboxyl groups, and that the conjugate contains between 3 and 6 compounds carrying carboxyl groups per 10 monomer units~~.

89. Conjugate corresponding to one or more of Claims 1 to 67, for use as a medicament.

910. Conjugate corresponding to Claim 89, wherein the medicament is for targeting of the kidney.

101. Macromolecule conjugate composed of at least two conjugates corresponding to one or more of Claims 1 to 67 which are covalently bonded to a macromolecule.

112. Use of a conjugate corresponding to one or more of Claims 1 to 67 in the manufacture of a medicament for the treatment of a kidney.

123. An image-enhancing composition at least comprising a conjugate corresponding to one or more of Claims 1 to 67.